Senate Approves ‘Right-To-Try’ Drug Bill

The Senate approved a bill that would allow seriously ill patients in all 50 states to request access to experimental medicines without FDA approval, Politico writes.

Sen. Ron Johnson’s measure, S. 204 (115), would authorize the use of unapproved medicines by patients diagnosed with a life-threatening illness as long as the drugs in question have already gone through preliminary testing on humans and continue to be evaluated in research the FDA oversees.

Eligible patients would have to exhaust other treatment options and be unable to participate in ongoing clinical trials.

The Senate’s unanimous approval follows a nationwide lobbying effort by the libertarian Goldwater Institute, which got similar right-to-try laws passed in 37 states. Vice President Mike Pence, who signed a right-to-try law while governor of Indiana, also has endorsed the federal effort. Reps. Andy Biggs of Arizona and Brian Fitzpatrick of Pennsylvania have a companion billpending in the House.

Johnson’s Trickett Wendler, Frank Mongiello and Jordan McLinn Right to Try Act of 2017 aroused concern from the drug industry, public health advocates and some at the FDA, who said it could undermine patient safety and drug development efforts. Drug companies wouldn’t be required to give patients medicine under the law, but it would remove a requirement that companies and physicians obtain the FDA’s sign-off to treat patients with experimental medicines.

The measure is broader than some state laws, because it covers patients with serious but not imminently deadly conditions, such as muscular dystrophy.

Johnson (R-Wis.) threatened to hold up a five-year reauthorization of FDA user fee programs if he didn’t get a vote on the bill. Senate leaders and the Senate Committee on Health, Education, Labor and Pensions struck a compromise under which Johnson got a vote on a revised version of his bill, separate from the FDA user fee bill, which was approved on a 94-1 vote earlier Thursday.

“We tried to run it by everybody who was affected,” HELP Chairman Lamar Alexander said. He added that Johnson did “a skillful job of legislating” to get a result.

The compromise included major changes to Johnson’s original proposal to satisfy skeptics’ concerns. Among other tweaks, the bill now requires FDA to receive reports of safety events that occur in right-to-try situations. It also forbids patients from being charged more than the cost of production for the medicines.

Separately, the FDA reauthorization bill included a proposal from Sens. Elizabeth Warren (D-Mass.) and Chuck Grassley (R-Iowa) that would make certain hearing aids available over the counter and make it easier for consumers to obtain them.

Despite some early objections from gun rights and conservative groups, the legislation passed with far-reaching support from both ends of the Capitol.

“Everyone leaned forward and said this is the kind of change that will help bring down health care costs in America,” Warren said in an interview. “Forty-eight million Americans have hearing loss, but fewer than one in six gets a hearing aid that could help them and the principal reason is because they can’t afford it.”

Senate Approves ‘Right-To-Try’ Drug Bill - overview

Summary: The Senate approved a bill Thursday that would allow seriously ill patients in all 50 states to request access to experimental medicines without Food and Drug Administration approval.

Sen. Ron Johnson’s measure, S. 204 (115), would authorize the use of unapproved medicines by patients diagnosed with a life-threatening illness as long as the drugs in question have already gone through preliminary testing on humans and continue to be evaluated in research the FDA oversees. Eligible patients would have to exhaust other treatment options and be unable to participate in ongoing clinical trials.

Consider the life of a chef on the road. Even when they’re not doing “research” for an upcoming project—trips that are essentially designed for overeating and drinking—they’re still likely seeking the best of what got them into the industry in the first place: damn good food.

The proliferation of low-cost airlines flying out of the U.S. means that it’s now possible to hop to Europe for as low as half the price charged by major carriers, the New York Times writes. But there’s always a trade-off — and it pays to comparison-shop, according to the publication.

Featured Contributors

Chasing snake oil and fad gurus is harmless until your journey of personal discovery becomes a platform for prescribing therapies to complete strangers. Any reasonably diligent venture capital partner should be weighing the risks.

Shkreli — who famously insulted members of Congress earlier this year but refused to testify officially over his own decision to increase the price of a life-saving pill — is now hopping at the chance to defend generic drug manufacturer Mylan.
He may even have opened the door to testify before the House Committee on Oversight and Government Reform, where he previously cited his Fifth Amendment's right to avoid incriminating himself.
"Any chance i can come through this time and actually testify?" he tweeted Thursday in a post directed at the committee's Democrats.
All of this now paves an unlikely new friendship between Shkreli and Mylan CEO Heather Bresch.
Heather Bresch created about $15 billion in value for Mylan in the seven years since she stepped up as president of the company. A big part of that value add came from her talent for repackaging off-the-shelf drugs into bona fide blockbusters.

Donald Trump is talking about Hillary Clinton’s health, as are two doctors who havenever evaluated Clinton. They have apparently diagnosed her with all kinds of ailments using the long disproven Fox-Drudge equation.
This attention on Clinton has renewed some interest in the letter Donald Trump released last year from his personal physician.

Even as doctors enter a medical field with more paying patients under the Affordable Care Act and unprecedented numbers of job opportunities, 25 percent of “newly trained physicians” would still choose another field if they could, according to a new analysis.